BioCentury
ARTICLE | Financial News

Microbiome company Anaeropharma raises $13.2M

July 5, 2017 7:01 PM UTC

Microbiome and cancer play Anaeropharma Science Inc. (Tokyo, Japan) raised $13.2 million from new investors Novartis AG (NYSE:NVS; SIX:NOVN), Shinsei Corporate Investment and Seventure Partners’ Health for Life Capital. Existing investors Innovation Network Corp. of Japan and Mitsubishi UFJ Capital also participated.

Anaeropharma is developing bacteria-based therapeutics that target hypoxic microenvironments in solid tumors. Its lead candidate, APS001F, is in a Phase Ib/IIa study to treat advanced solid tumors. The product is recombinant anaerobic bacteria Bifidobacterium longum modified to express the cytosine deaminase (CD) gene...

BCIQ Company Profiles

Anaeropharma Science Inc.